<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630731</url>
  </required_header>
  <id_info>
    <org_study_id>MCCRENT</org_study_id>
    <nct_id>NCT03630731</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma</brief_title>
  <official_title>Maintenance Treatment of Chidamide in Chemotherapy-responded Stage IV or Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extranodal natural killer/T-cell lymphoma, nasal type (NKTCL) is a highly aggressive&#xD;
      peripheral T-cell lymphoma (PTCL). Patients with newly diagnosed stage IV and&#xD;
      relapsed/refractory have poor prognosis. 5-year progression-free survival was reported only&#xD;
      55%. Chidamide is a selective histone deacetylase inhibitor which was approved by FDA in&#xD;
      treating relapsed or refractory PTCL. In phase I and II studies of chidamide, patients with&#xD;
      relapsed or refractory NKTCL achieved a higher overall remission. Patients who obtained&#xD;
      complete or partial remission had much favourable duration of remission. Thus, the invesgator&#xD;
      design this study to evaluate the role of maintenance treatment of chidamide for induction&#xD;
      chemotherapy-responded newly-diagnosed advanced and relapsed/refractory NKTCL patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>PFS was defined as the period from the date of treatment till the date of disease progression, relapse, or death from any cause.</description>
  </primary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chidamide</intervention_name>
    <description>For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. diagnosis of NKTCL with typical morphology and immunophenotype, according to the 2008&#xD;
             World Health Organization classification of lymphomas;&#xD;
&#xD;
          2. newly-diagnosed stage IV disease or relapsed or refractory disease；&#xD;
&#xD;
          3. age ≥ 18 years;&#xD;
&#xD;
          4. ECOG performance status 0-2;&#xD;
&#xD;
          5. at least one measurable lesion;&#xD;
&#xD;
          6. adequate hematological, hepatic, and renal functions; e.g., absolute neutrophil count&#xD;
             ≥ 1.5 × 109/L, platelet count ≥ 80 × 109/L, total bilirubin ≤ 1.5 × upper limit of&#xD;
             normal, alanine transaminase and aspartate transaminase ≤ 2 × upper limit of normal,&#xD;
             and creatinine ≤ 1.5 mg/dl;&#xD;
&#xD;
          7. life expectancy of more than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with newly-diagnosed stage I-II disease;&#xD;
&#xD;
          2. pregnancy or lactation;&#xD;
&#xD;
          3. any coexisting medical problems of sufficient severity to prevent full compliance with&#xD;
             the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei Dong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, Chinese ACademy of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei Dong</last_name>
    <phone>13811929322</phone>
    <email>dongmei030224@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Dong</last_name>
      <phone>(86)13811929322</phone>
      <email>dongmei030224@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mei Dong</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

